JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non‐small cell lung cancer with activating EGFR mutations. However, even in patients with an initial dramatic response to such a drug, acquired resistance develops after 6–12 months...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancer Sci
Κύριοι συγγραφείς: Harada, Daijiro, Takigawa, Nagio, Ochi, Nobuaki, Ninomiya, Takashi, Yasugi, Masayuki, Kubo, Toshio, Takeda, Hiromasa, Ichihara, Eiki, Ohashi, Kadoaki, Takata, Saburo, Tanimoto, Mitsune, Kiura, Katsuyuki
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley and Sons Inc. 2012
Θέματα:
Original Articles
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659254/
https://ncbi.nlm.nih.gov/pubmed/22712764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02363.x
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια